Stock Events

Replicel Life Sciences 

$0.04
2
+$0+0% Wednesday 15:30

Statistics

Day High
0.05
Day Low
0.05
52W High
0.19
52W Low
0.03
Volume
1,456
Avg. Volume
5,333
Mkt Cap
3.11M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

1MayExpected
Q3 2021
Q1 2022
Q2 2022
Q3 2022
Q2 2023
Q3 2023
Next
-0.03
-0.03
-0.03
-0.02
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow REPCF. It's not an investment recommendation.

About

Precious Metals
Non-Energy Minerals
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Show more...
CEO
Country
CA
ISIN
CA76027P4006
WKN
000A2APX7

Listings